NASDAQ:SRDX

Surmodics (SRDX) Stock Forecast, Price & News

$17.67

-0.06 (-0.34%)

(As of 05/26/2023 04:00 PM ET)

Compare

Today's Range: $17.43
▼
$17.83
50-Day Range: $17.13
▼
$24.23
52-Week Range: $16.00
▼
$40.21

Volume: 62,800 shs
Average Volume: 147,071 shs
Market Capitalization: $249.68 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $47.00

Surmodics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 166.0% Upside
$47.00 Price Target
Short Interest: Healthy
1.84% of Float Sold Short
Dividend Strength: N/A
Sustainability: -2.52
Upright™ Environmental Score
News Sentiment: 0.63
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.85) to ($1.03) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.36 out of 5 stars

Medical Sector

265th out of 1,010 stocks

Surgical & Medical Instruments Industry

26th out of 104 stocks

3.3

Analyst's Opinion

Consensus Rating
Surmodics has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $47.00, Surmodics has a forecasted upside of 166.0% from its current price of $17.67.
Amount of Analyst Coverage
Surmodics has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
1.84% of the float of Surmodics has been sold short.
Short Interest Ratio / Days to Cover
Surmodics has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Surmodics has recently decreased by 6.87%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Surmodics does not currently pay a dividend.
Dividend Growth
Surmodics does not have a long track record of dividend growth.

3.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Surmodics has received a 38.03% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Synthetic antigens", " Coatings for drug delivery devices", and "Medical equipment engineering" products. See details.
Environmental Sustainability
The Environmental Impact score for Surmodics is -2.52.

2.6

News and Social Media Coverage

News Sentiment
Surmodics has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Surmodics this week, compared to 1 article on an average week.
MarketBeat Follows
2 people have added Surmodics to their MarketBeat watchlist in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Surmodics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 7.50% of the stock of Surmodics is held by insiders.
Percentage Held by Institutions
96.49% of the stock of Surmodics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Surmodics are expected to grow in the coming year, from ($1.85) to ($1.03) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Surmodics is -6.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Surmodics is -6.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Surmodics has a P/B Ratio of 2.28. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Surmodics (NASDAQ:SRDX) Stock

Surmodics, Inc. engages in the provision of surface modification technologies for intravascular medical devices and chemical components for in vitro diagnostic immunoassay tests and microarrays. It also develops and commercializes medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. The firm operates through the following segments: Medical Device, In Vitro Diagnostics, and Corporate. The Medical Device segment designs, develops, and manufactures interventional medical devices, surface modification coating technologies, as well as drug-delivery coating technologies. The In Vitro Diagnostics segment is composed of component products and technologies for diagnostic test kits and biomedical research applications. The company was founded in June 1979 and is headquartered in Eden Prairie, MN.

Receive SRDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Surmodics and its competitors with MarketBeat's FREE daily newsletter.

SRDX Stock News Headlines

May 25, 2023 | finance.yahoo.com

Surmodics to Participate in the Jefferies Healthcare Conference on June 8

May 22, 2023 | americanbankingnews.com

Surmodics (NASDAQ:SRDX) Now Covered by StockNews.com

May 30, 2023 | Edge On The Street (Ad)

The Largest Ever Technology Wave Is Coming!

This summer, a small tech company will launch a key technology to advance artificial intelligence, or AI, that can think, reason and make decisions like humans. It will change the world, just like electricity did.

May 16, 2023 | finance.yahoo.com

Here's Why SurModics (SRDX) Is a Great 'Buy the Bottom' Stock Now

May 15, 2023 | finance.yahoo.com

Down -18.32% in 4 Weeks, Here's Why You Should You Buy the Dip in SurModics (SRDX)

May 14, 2023 | finance.yahoo.com

In the wake of Surmodics, Inc.'s (NASDAQ:SRDX) latest US$31m market cap drop, institutional owners may be forced to take severe actions

May 14, 2023 | americanbankingnews.com

Surmodics, Inc. (NASDAQ:SRDX) Sees Large Decline in Short Interest

May 12, 2023 | msn.com

Surmodics files for $200M mixed shelf offering

May 30, 2023 | Edge On The Street (Ad)

How to Invest in AI's Fast-Growing Market

The AI market stands at $160 billion in 2023. Estimates are the AI market will grow 20-fold to $1.8 TRILLION by 2030. One little-known company is looking to win big with a new network technology no one else has. AI could explode... and soon.

May 3, 2023 | finance.yahoo.com

Surmodics, Inc. (NASDAQ:SRDX) Q2 2023 Earnings Call Transcript

May 2, 2023 | americanbankingnews.com

Q3 2023 Earnings Forecast for Surmodics, Inc. (NASDAQ:SRDX) Issued By Barrington Research

April 30, 2023 | msn.com

Surmodics's Return on Invested Capital Insights

April 30, 2023 | marketwatch.com

When the Price of Surmodics $SRDX Talks, People Listen

April 27, 2023 | finance.yahoo.com

Surmodics (SRDX) Q2 Earnings Top Estimates, FY23 View Revised

April 25, 2023 | americanbankingnews.com

Surmodics (SRDX) Scheduled to Post Earnings on Wednesday

April 17, 2023 | finance.yahoo.com

Surmodics, Inc. (NASDAQ:SRDX) Stocks Shoot Up 36% But Its P/S Still Looks Reasonable

April 10, 2023 | finance.yahoo.com

Investors in Surmodics (NASDAQ:SRDX) have unfortunately lost 44% over the last year

March 29, 2023 | finance.yahoo.com

Surmodics (SRDX) Gets FDA's Formal Feedback About SurVeil DCB

March 28, 2023 | finance.yahoo.com

Surmodics Provides Regulatory Update on its Strategy to Submit an Amended Premarket Approval Application for the SurVeil™ Drug-Coated Balloon

March 18, 2023 | benzinga.com

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Surmodics Inc. Investors to Inquire About Securities Class Action Investigation - SRDX

March 17, 2023 | finance.yahoo.com

SurModics (SRDX) Moves 5.4% Higher: Will This Strength Last?

March 8, 2023 | finance.yahoo.com

SurModics (SRDX) Down 37.2% Since Last Earnings Report: Can It Rebound?

February 25, 2023 | benzinga.com

ROSEN, National Trial Lawyers, Encourages Surmodics Inc. Investors to Inquire About Securities Class Action Investigation - SRDX

February 17, 2023 | benzinga.com

ROSEN, Global Investor Counsel, Encourages Surmodics Inc. Investors to Inquire About Securities Class Action Investigation - SRDX

February 9, 2023 | benzinga.com

NATIONALLY RANKED ROSEN LAW FIRM Encourages Surmodics Inc. Investors to Inquire About Securities Class Action Investigation – SRDX

February 9, 2023 | insidermonkey.com

Surmodics, Inc. (NASDAQ:SRDX) Q1 2023 Earnings Call Transcript

February 8, 2023 | msn.com

Surmodics's Return On Capital Employed Insights

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive SRDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Surmodics and its competitors with MarketBeat's FREE daily newsletter.

SRDX Company Calendar

Last Earnings: 2/06/2023
Today: 5/30/2023
Next Earnings (Estimated): 7/26/2023
Fiscal Year End: 9/30/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: Health Care Equipment
Sector: Medical
Current Symbol: NASDAQ:SRDX
CUSIP: 86887310
CIK: 924717
Web: www.surmodics.com
Phone: (952) 500-7000
Fax: 952-500-7001
Employees: 389
Year Founded: 1979

Price Target and Rating

Average Stock Price Forecast: $47.00
High Stock Price Forecast: $60.00
Low Stock Price Forecast: $34.00
Forecasted Upside/Downside: +166.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.58)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-27,270,000.00
Net Margins: -34.92%
Pretax Margin: -28.50%
Return on Equity: -18.98%
Return on Assets: -12.56%

Debt

Debt-to-Equity Ratio: 0.29
Current Ratio: 3.20
Quick Ratio: 2.48

Sales & Book Value

Annual Sales: $99.95 million
Price / Sales: 2.50
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $7.75 per share
Price / Book: 2.28

Miscellaneous

Outstanding Shares: 14,130,000
Free Float: 13,073,000
Market Cap: $249.68 million
Optionable: Optionable
Beta: 1.02

Social Links

Key Executives

Gary R. Maharaj
President, Chief Executive Officer & Director

Timothy J. Arens
CFO, SVP-Finance & Information Technology

Charles W. Olson
President-Medical Device Coatings & SVP

Teri L. W. Sides
President-Vascular Interventions & SVP

John D. Manders
Vice President-Finance & Controller

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SRDX Stock - Frequently Asked Questions

Should I buy or sell Surmodics stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Surmodics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" SRDX shares.
View SRDX analyst ratings or view top-rated stocks.
What is Surmodics' stock price forecast for 2023?: 2 Wall Street research analysts have issued twelve-month target prices for Surmodics' stock. Their SRDX share price forecasts range from $34.00 to $60.00. On average, they anticipate the company's share price to reach $47.00 in the next twelve months. This suggests a possible upside of 166.0% from the stock's current price.
View analysts price targets for SRDX or view top-rated stocks among Wall Street analysts.
How have SRDX shares performed in 2023?: Surmodics' stock was trading at $34.12 at the start of the year. Since then, SRDX shares have decreased by 48.2% and is now trading at $17.67.
View the best growth stocks for 2023 here.
When is Surmodics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 26th 2023.
View our SRDX earnings forecast.
How were Surmodics' earnings last quarter?: Surmodics, Inc. (NASDAQ:SRDX) issued its quarterly earnings data on Monday, February, 6th. The company reported ($0.50) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.63) by $0.13. The firm earned $24.93 million during the quarter, compared to analyst estimates of $24.19 million. Surmodics had a negative net margin of 34.92% and a negative trailing twelve-month return on equity of 18.98%. During the same period in the prior year, the firm posted ($0.13) earnings per share.
What ETFs hold Surmodics' stock?: ETFs with the largest weight of Surmodics (NASDAQ:SRDX) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS), SPDR S&P Health Care Equipment ETF (XHE).iShares U.S. Medical Devices ETF (IHI) and
What guidance has Surmodics issued on next quarter's earnings?: Surmodics updated its FY 2023 earnings guidance on Thursday, April, 27th. The company provided earnings per share guidance of -$1.98--$1.68 for the period, compared to the consensus estimate of -$1.90. The company issued revenue guidance of $103.00 million-$106.00 million, compared to the consensus revenue estimate of $104.34 million.
What is Gary Maharaj's approval rating as Surmodics' CEO?: 8 employees have rated Surmodics Chief Executive Officer Gary Maharaj on Glassdoor.com. Gary Maharaj has an approval rating of 65% among the company's employees.

What other stocks do shareholders of Surmodics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Surmodics investors own include Gilead Sciences (GILD), Netflix (NFLX), Exelixis (EXEL), Intel (INTC), NVIDIA (NVDA), Tandem Diabetes Care (TNDM), uniQure (QURE), Sangamo Therapeutics (SGMO), Abbott Laboratories (ABT) and Dynavax Technologies (DVAX).
What is Surmodics' stock symbol?: Surmodics trades on the NASDAQ under the ticker symbol "SRDX."
Who are Surmodics' major shareholders?: Surmodics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Trigran Investments Inc. (16.69%), BlackRock Inc. (7.18%), Renaissance Technologies LLC (4.48%), Dimensional Fund Advisors LP (3.00%), State Street Corp (2.55%) and Segall Bryant & Hamill LLC (2.31%). Insiders that own company stock include Charles W Olson, Charles W Olson, David Dantzker, Gary R Maharaj, Gary R Maharaj, John D Manders, Jose H Bedoya, Jose H Bedoya, Joseph J Stich, Joseph J Stich and Ronald B Sr Kalich Sr.
View institutional ownership trends.
How do I buy shares of Surmodics?: Shares of SRDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Surmodics' stock price today?: One share of SRDX stock can currently be purchased for approximately $17.67.
How much money does Surmodics make?: Surmodics (NASDAQ:SRDX) has a market capitalization of $249.68 million and generates $99.95 million in revenue each year. The company earns $-27,270,000.00 in net income (profit) each year or ($2.58) on an earnings per share basis.
How many employees does Surmodics have?: The company employs 389 workers across the globe.
How can I contact Surmodics?: Surmodics' mailing address is 9924 WEST 74TH STREET, EDEN PRAIRIE MN, 55344. The official website for the company is www.surmodics.com. The company can be reached via phone at (952) 500-7000, via email at ir@surmodics.com, or via fax at 952-500-7001.

This page (NASDAQ:SRDX) was last updated on 5/30/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial